

# TEZPELUMAB DESENSITIZATION PROTOCOL IN A PATIENT ALLERGIC TO POLYSORBATE: A CASE REPORT

M. Vázquez Vázquez<sup>1</sup>, M.B. Feal Cortizas<sup>1</sup>, M. Mateos Salvador<sup>1</sup>, M.M. Calvín Lamas<sup>1</sup>, A. Torres Pérez, M. Neira Rodríguez-Hermida<sup>1</sup>, C. Fenández Diz<sup>1</sup>, E. Gómez Costa<sup>1</sup>, L. Caeiro Martínez<sup>1</sup>, L. Margusino Framiñán<sup>2</sup>.

<sup>1</sup>A Coruña University Hospital Complex, Pharmacy Department, A Coruña, Spain. <sup>2</sup>Research Group of Hospital Pharmacy. Biomedical Research Institute A Coruña INIBIC. A Coruña University.

## BACKGROUND AND IMPORTANCE


- **Tezepelumab** is an **anti-TSLP** monoclonal antibody used in uncontrolled severe asthma.
- Hypersensitivity to excipients in biological therapies is a significant clinical challenge.



Shared components among biological drugs.



Hospital pharmacy role: desensitization protocols, ensuring traceability, maintaining process safety



## AIM AND OBJECTIVES

To describe a subcutaneous desensitization protocol to tezepelumab in a patient with severe asthma and polysorbate hypersensitivity.

## MATERIALS AND METHODS

- A 48-year-old with severe asthma and allergic to **polysorbate 80**
- Previous treatments: omalizumab and dupilumab (both ineffective), benralizumab allergic reaction (polysorbate 20) and reslizumab (ineffective; the only without polysorbate)

## RESULTS

Commercial pen (CP) ( 210 mg/1.91 mL)




SOL A	0,71 mL CP + 0,29 mL SS*
SOL B	0,61 mL CP + 0,39 mL SS
SOL X**	0,59 mL CP + 2,51 mL SS

\*SS:Saline solution 0,9%

\*\*Five dilutions were prepared from solution X

Preparation: laminar flow cabin

Quality control:



- Each dilution subcutaneous every 20 min
- Total duration: 140 min
- Total dose: 210 mg
- Every 4 weeks

## CONCLUSIONS AND RELEVANCE

- Essential role of pharmacy service: development of a desensitization protocol.
- This case contributes valuable evidence in a field with limited published data.

